Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

UroGen Pharma (URGN) Receivables - Net (2016 - 2025)

UroGen Pharma's Receivables - Net history spans 7 years, with the latest figure at $33.1 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 62.95% year-over-year to $33.1 million; the TTM value through Dec 2025 reached $33.1 million, up 62.95%, while the annual FY2025 figure was $33.1 million, 62.95% up from the prior year.
  • Receivables - Net reached $33.1 million in Q4 2025 per URGN's latest filing, up from $19.7 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $33.1 million in Q4 2025 to a low of $6.3 million in Q1 2021.
  • Average Receivables - Net over 5 years is $15.1 million, with a median of $13.5 million recorded in 2023.
  • Peak YoY movement for Receivables - Net: skyrocketed 2266.17% in 2021, then decreased 13.59% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $11.7 million in 2021, then grew by 8.42% to $12.7 million in 2022, then grew by 21.56% to $15.4 million in 2023, then soared by 31.46% to $20.3 million in 2024, then skyrocketed by 62.95% to $33.1 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Receivables - Net are $33.1 million (Q4 2025), $19.7 million (Q3 2025), and $19.6 million (Q2 2025).